Unbound MEDLINE

HIV-1 subtype B Tat gene activities and disease progression in HIV-1 CRF01_AE infection. The Southeast Asian journal of tropical medicine and public health [Southeast Asian J Trop Med Public Health] Journal article

 
TitleHIV-1 subtype B Tat gene activities and disease progression in HIV-1 CRF01_AE infection.
Author(s)Niyasom C, Horthongkham N, Sreephiang A, Kantakamalakul W, Louisirirotchanakul S, Chuenchitra T, Sutthent R 
InstitutionDepartment of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
SourceSoutheast Asian J Trop Med Public Health 2009 Jul; 40(4):748-58.
AbstractHIV-1 tat gene function and immunogenicity of HIV-1 Tat protein from 3 low (PS01, PS40, PS58) and 3 high (PS19, PS65, LP22) viral load infected, untreated and asymptomatic individuals from Thailand were compared. Levels of Tat-dependent chloramphenicol acetyltransferase (CAT) induced in HL3T1 cells with tat1 gene from HIV-1 isolates of high viral load group was significantly higher than those from low viral load group. HIV-1 subtype determination using env (C2-V4) gene demonstrated that 2/3 (PS01 and PS40) and 1/3 (PS58) from low viral load group were CRF01_AE and subtype B, while all 3 HIV-1 isolates from high viral load group were CRF01_AE. However, all 3 HIV-1 tat nucleotide sequences from low viral load group, which contained env CRF01_AE sequence, belonged to subtype B whereas all those from high viral load group contained CRF01_AE sequence. HIV Tat recombinant proteins from these groups were tested for immunogenicity in mice. All recombinant Tat proteins (except from PS58) were immunogenic in a dose-dependent manner, but with significantly differences of the immunogenicity levels between high and low viral load groups. These results indicated that HIV-1 subtype B tat gene activities might be associated with reduced disease progression of HIV-1 CRF01_AE infected individuals.
Languageeng
Pub Type(s)Journal Article
Research Support, Non-U.S. Gov't
PubMed ID19842409
  
Advertise on this site.